Literature DB >> 29902559

Role of Daily Plan Adaptation in MR-Guided Stereotactic Ablative Radiation Therapy for Adrenal Metastases.

Miguel A Palacios1, Omar Bohoudi2, Anna M E Bruynzeel2, John R van Sörsen de Koste2, Paul Cobussen2, Ben J Slotman2, Frank J Lagerwaard2, Suresh Senan2.   

Abstract

PURPOSE: To study interfractional organ changes during magnetic resonance (MR)-guided stereotactic ablative radiation therapy for adrenal metastases and to evaluate the dosimetric advantages of online plan adaptation. METHODS AND MATERIALS: Seventeen patients underwent a total of 84 fractions of video-assisted, respiration-gated, MR-guided adaptive radiation therapy to deliver either 50 Gy (5 fractions), 60 Gy (8 fractions), or 24 Gy (3 fractions). An MR scan was repeated before each fraction, followed by rigid coregistration to the gross tumor volume (GTV) on the pretreatment MR scan. Contour deformation, planning target volume (PTV) (GTV + 3 mm) expansion, and online plan reoptimization were then performed. Reoptimized plans were compared with baseline treatment plans recalculated on the anatomy-of-the-day ("predicted plans"). Interfractional changes in organs at risk (OARs) were quantified according to OAR volume changes within a 3 cm distance from the PTV surface, center of mass displacements, and the Dice similarity coefficient. Plan quality evaluation was based on target coverage (GTV and PTV) and high dose sparing of all OARs (V36Gy, V33Gy, and V25Gy).
RESULTS: Substantial center of mass displacements were observed for stomach, bowel, and duodenum, 17, 27 and 36 mm, respectively. Maximum volume changes for the stomach, bowel, and duodenum within 3 cm of PTV were 23.8, 20.5, and 20.9 cm3, respectively. Dice similarity coefficient values for OARs ranged from 0.0 to 0.9 for all fractions. Baseline plans recalculated on anatomy-of-the-day revealed underdosage of target volumes and variable OAR sparing, leading to a failure to meet institutional constraints in a third of fractions. Online reoptimization improved target coverage in 63% of fractions and reduced the number of fractions not meeting the V95% objective for GTV and PTV. Reoptimized plans exhibited significantly better sparing of OARs.
CONCLUSIONS: Significant interfractional changes in OAR positions were observed despite breath-hold stereotactic ablative radiation therapy delivery under MR-guidance. Online reoptimization of treatment plans led to significant improvements in target coverage and OAR sparing.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29902559     DOI: 10.1016/j.ijrobp.2018.06.002

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

Review 1.  Proton therapy delivery: what is needed in the next ten years?

Authors:  Andries N Schreuder; Jacob Shamblin
Journal:  Br J Radiol       Date:  2019-11-14       Impact factor: 3.039

Review 2.  The transformation of radiation oncology using real-time magnetic resonance guidance: A review.

Authors:  William A Hall; Eric S Paulson; Uulke A van der Heide; Clifton D Fuller; B W Raaymakers; Jan J W Lagendijk; X Allen Li; David A Jaffray; Laura A Dawson; Beth Erickson; Marcel Verheij; Kevin J Harrington; Arjun Sahgal; Percy Lee; Parag J Parikh; Michael F Bassetti; Clifford G Robinson; Bruce D Minsky; Ananya Choudhury; Robert J H A Tersteeg; Christopher J Schultz
Journal:  Eur J Cancer       Date:  2019-10-12       Impact factor: 9.162

3.  First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany.

Authors:  Sebastian Klüter; Sonja Katayama; C Katharina Spindeldreier; Stefan A Koerber; Gerald Major; Markus Alber; Sati Akbaba; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Strahlenther Onkol       Date:  2020-01-30       Impact factor: 3.621

4.  Treatment plan quality during online adaptive re-planning.

Authors:  Janita E van Timmeren; Madalyne Chamberlain; Jérôme Krayenbuehl; Lotte Wilke; Stefanie Ehrbar; Marta Bogowicz; Callum Hartley; Mariangela Zamburlini; Nicolaus Andratschke; Helena Garcia Schüler; Matea Pavic; Panagiotis Balermpas; Chaehee Ryu; Matthias Guckenberger; Stephanie Tanadini-Lang
Journal:  Radiat Oncol       Date:  2020-08-21       Impact factor: 3.481

Review 5.  "Après Mois, Le Déluge": Preparing for the Coming Data Flood in the MRI-Guided Radiotherapy Era.

Authors:  Kendall J Kiser; Benjamin D Smith; Jihong Wang; Clifton D Fuller
Journal:  Front Oncol       Date:  2019-09-30       Impact factor: 6.244

6.  Three discipline collaborative radiation therapy (3DCRT) special debate: Equipment development is stifling innovation in radiation oncology.

Authors:  Leonard Kim; Stephanie Markovina; Samantha J Van Nest; Subarna Eisaman; Lakshmi Santanam; Julie M Sullivan; Michael Dominello; Michael C Joiner; Jay Burmeister
Journal:  J Appl Clin Med Phys       Date:  2019-05-25       Impact factor: 2.102

7.  Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Rohann J M Correa; Famke Schneiders; Cornelis J A Haasbeek; George B Rodrigues; Michael Lock; Brian P Yaremko; Glenn S Bauman; Belal Ahmad; Devin Schellenberg; Mitchell Liu; Stewart Gaede; Joanna Laba; Liam Mulroy; Sashendra Senthi; Alexander V Louie; Anand Swaminath; Anthony Chalmers; Andrew Warner; Ben J Slotman; Tanja D de Gruijl; Alison Allan; Suresh Senan
Journal:  BMC Cancer       Date:  2019-08-19       Impact factor: 4.430

8.  Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients.

Authors:  Laila König; Matthias F Häfner; Sonja Katayama; Stefan A Koerber; Eric Tonndorf-Martini; Denise Bernhardt; Bastian von Nettelbladt; Fabian Weykamp; Philipp Hoegen; Sebastian Klüter; Matthew S Susko; Jürgen Debus; Juliane Hörner-Rieber
Journal:  Radiat Oncol       Date:  2020-02-04       Impact factor: 3.481

Review 9.  Master Protocol Trial Design for Efficient and Rational Evaluation of Novel Therapeutic Oncology Devices.

Authors:  Danielle S Bitterman; Daniel N Cagney; Lisa L Singer; Paul L Nguyen; Paul J Catalano; Raymond H Mak
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

10.  Stereotactic body radiation therapy (SBRT) of adrenal gland metastases in oligometastatic and oligoprogressive disease.

Authors:  Leonid B Reshko; Jeremy T Gaskins; Craig L Silverman; Neal E Dunlap
Journal:  Rep Pract Oncol Radiother       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.